Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 11/20 | 0.63 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213955 | 0.75 | OTUD7B (0.46) | CDK5ALDH1A1CCNE1CDK2MAPT | |
| SCHEMBL29739274 | 0.73 | DEGS1 (0.46) | CDK5ALDH1A1RAB9ACCNE1CDK2 | |
| SCHEMBL1269214 | 0.73 | CDK5 (0.57) | CDK5CDK5R1GSK3B | |
| SCHEMBL6216418 | 0.70 | NPY5R (0.45) | CDK5ALDH1A1RAB9ACCNE1CDK2 | |
| SCHEMBL6215219 | 0.70 | NPY5R (0.46) | CDK5ALDH1A1RAB9ACCNE1CDK2 | |
| SCHEMBL11966195 | 0.68 | RAB9A (0.45) | ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL29177237 | 0.68 | ALDH1A1 (0.59) | ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL16775795 | 0.68 | ALDH1A1 (0.43) | CDK5ALDH1A1RAB9ACCNE1CDK2 | |
| SCHEMBL1011540 | 0.68 | RAB9A (0.59) | ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL31286005 | 0.68 | RAB9A (0.59) | ALDH1A1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078529-B2 | N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 | PFIZER INC. (US) | 2006-07-18 | — | — | US | claimed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | claimed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | claimed |
| US-7078529-B2 | N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 | PFIZER INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20060149066-A1 | Imidazole derivatives | PFIZER INC | 2006-07-06 | — | — | US | disclosed |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6756385-B2 | FERTILITY; ANTIDIABETIC AGENTS | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030083352-A1 | Synthesis of imidazole intermediates | PFIZER INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083352-A1 | Synthesis of imidazole intermediates | CDK1, CDK2, CDK3 | CDK5 4/4885CDK5R1 16/4885GSK3B 9/4885 |
| US-20060149066-A1 | Imidazole derivatives | CDK1, CDK3, CKMT1A; CKMT1B | CDK5 6/4885CDK5R1 11/4885GSK3B 14/4885 |
| US-20020119963-A1 | Imidazole derivatives | CDK1, CDK3, CDK2 | CDK5 4/4885CDK5R1 16/4885GSK3B 6/4885 |
| US-20040192750-A1 | Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease | CDK1, CDK3, CDK5 | CDK5 3/4885CDK5R1 9/4885GSK3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.